BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol. 2010;2:a001016. [PMID: 20300207 DOI: 10.1101/cshperspect.a001016] [Cited by in Crossref: 185] [Cited by in F6Publishing: 212] [Article Influence: 15.4] [Reference Citation Analysis]
Number Citing Articles
1 Gao F, Yu B, Rao B, Sun Y, Yu J, Wang D, Cui G, Ren Z. The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1051987] [Reference Citation Analysis]
2 Jiang Y, Bi J, Wu M, Ye S, Hu L, Yi Y, Wang H, Wang L. In vitro anti-hepatocellular carcinogenesis of 1,2,3,4,6-Penta-O- galloyl-β-D-glucose.. [DOI: 10.21203/rs.3.rs-1645156/v2] [Reference Citation Analysis]
3 Li J, Ek F, Olsson R, Belting M, Bengzon J. Glioblastoma CD105+ cells define a SOX2- cancer stem cell-like subpopulation in the pre-invasive niche. Acta Neuropathol Commun 2022;10:126. [PMID: 36038950 DOI: 10.1186/s40478-022-01422-8] [Reference Citation Analysis]
4 Liao F, Yuan L, Zhu J, Chen W, Zhao Y, He J, D'alessandris QG. Association of TP53 rs1042522 C>G Polymorphism with Glioma Risk in Chinese Children. BioMed Research International 2022;2022:1-6. [DOI: 10.1155/2022/2712808] [Reference Citation Analysis]
5 Mak TK, Li X, Huang H, Wu K, Huang Z, He Y, Zhang C. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer. Front Immunol 2022;13:951214. [DOI: 10.3389/fimmu.2022.951214] [Reference Citation Analysis]
6 Jiang M, Wu X, Bao S, Wang X, Qu F, Liu Q, Huang X, Li W, Tang J, Yin Y. Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer. Front Immunol 2022;13:946468. [DOI: 10.3389/fimmu.2022.946468] [Reference Citation Analysis]
7 Hu D, Zhang T, Yan Z, Wang L, Wang Y, Meng N, Tu B, Teng Y, Li Z, Lou X, Lei Y, Ren X, Zou Y, Wang F. Multimolecular characteristics of cell-death related hub genes in human cancers: a comprehensive pan-cancer analysis. Cell Cycle 2022;:1-11. [PMID: 35848940 DOI: 10.1080/15384101.2022.2101337] [Reference Citation Analysis]
8 Sun K, Zhu H, Chai W, Yan F. TP53 Mutation Estimation Based on MRI Radiomics Analysis for Breast Cancer. J Magn Reson Imaging 2022. [PMID: 35771720 DOI: 10.1002/jmri.28323] [Reference Citation Analysis]
9 Triantafyllidis CP, Barberis A, Cuervo AM, Charlton P, Hartley F, Van Bijsterveldt L, Gjerga E, Rodriguez JS, Buffa FM. Reconstructing the functional effect of TP53 somatic mutations on its regulon using causal signalling network modelling.. [DOI: 10.1101/2022.06.23.497293] [Reference Citation Analysis]
10 Xu S, Zhou Y, Luo J, Chen S, Xie J, Liu H, Wang Y, Li Z. Integrated Analysis of a Ferroptosis-Related LncRNA Signature for Evaluating the Prognosis of Patients with Colorectal Cancer. Genes (Basel) 2022;13:1094. [PMID: 35741856 DOI: 10.3390/genes13061094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Guo L, Kang Y, Xia D, Ren Y, Yang X, Xiang Y, Tang L, Ren D, Yu J, Wang J, Liang T. Characterization of Immune-Based Molecular Subtypes and Prognostic Model in Prostate Adenocarcinoma. Genes (Basel) 2022;13:1087. [PMID: 35741849 DOI: 10.3390/genes13061087] [Reference Citation Analysis]
12 Qin Y, Chen Y, Chen J, Xu K, Xu F, Shi J. The relationship between previous pulmonary tuberculosis and risk of lung cancer in the future. Infect Agent Cancer 2022;17:20. [PMID: 35525982 DOI: 10.1186/s13027-022-00434-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhang S, Carlsen L, Hernandez Borrero L, Seyhan AA, Tian X, El-deiry WS. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer. Biomolecules 2022;12:548. [DOI: 10.3390/biom12040548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Smith JC, Sheltzer JM. Genome-wide identification and analysis of prognostic features in human cancers. Cell Rep 2022;38:110569. [PMID: 35354049 DOI: 10.1016/j.celrep.2022.110569] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
15 Xu M, Chen Z, Lin B, Zhang S, Qu J. A seven-lncRNA signature for predicting prognosis in breast carcinoma. Transl Cancer Res 2021;10:4033-46. [PMID: 35116701 DOI: 10.21037/tcr-21-747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Schaafsma E, Takacs EM, Kaur S, Cheng C, Kurokawa M. Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature. Sci Rep 2022;12:1317. [PMID: 35079034 DOI: 10.1038/s41598-022-05243-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Dong H, Tan Q, Xu Y, Zhu Y, Yao Y, Wang Y, Li C, Li H, Zhang G, Xiong Y, Ruan M, Zhao J, Jin W, Lu L, Lu S. Convergent alteration of lung tissue microbiota and tumor cells in lung cancer. iScience 2022;25:103638. [PMID: 35005565 DOI: 10.1016/j.isci.2021.103638] [Reference Citation Analysis]
18 Wadhwa R, Paudel KR, Shukla S, Shastri M, Gupta G, Devkota HP, Chellappan DK, Hansbro PM, Dua K. Epigenetic Therapy as a Potential Approach for Targeting Oxidative Stress–Induced Non-Small-Cell Lung Cancer. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects 2022. [DOI: 10.1007/978-981-15-4501-6_106-2] [Reference Citation Analysis]
19 Anang V, Singh A, Kottarath SK, Verma C. Receptors of immune cells mediates recognition for tumors. Progress in Molecular Biology and Translational Science 2022. [DOI: 10.1016/bs.pmbts.2022.09.009] [Reference Citation Analysis]
20 Wadhwa R, Paudel KR, Shukla S, Shastri M, Gupta G, Devkota HP, Bebawy M, Chellappan DK, Hansbro PM, Dua K. Epigenetic Therapy as a Potential Approach for Targeting Oxidative Stress–Induced Non-small-Cell Lung Cancer. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects 2022. [DOI: 10.1007/978-981-15-9411-3_106] [Reference Citation Analysis]
21 Mohanty S, Heuser M. Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia. Cancers (Basel) 2021;13:6192. [PMID: 34944812 DOI: 10.3390/cancers13246192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Arvelo F, Sojo F, Cotte C. Cáncer y Microbiota. Invest Clin 2021;62:407-440. [DOI: 10.22209/ic.v62n4a09] [Reference Citation Analysis]
23 Neal A, Lai T, Singh T, Rahseparian N, Grogan T, Elashoff D, Scott P, Pellegrini M, Memarzadeh S. Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. Cancers (Basel) 2021;13:5908. [PMID: 34885017 DOI: 10.3390/cancers13235908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Noor H, Briggs NE, McDonald KL, Holst J, Vittorio O. TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy. Cancers (Basel) 2021;13:5362. [PMID: 34771529 DOI: 10.3390/cancers13215362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Sirotković-Skerlev M, Plavetić ND, Sedlić F, Kuna SK, Vrbanec D, Belev B, Pleština S, Kovač Z, Kulić A. Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years). Cancer Biomark 2021;30:95-104. [PMID: 32986661 DOI: 10.3233/CBM-201497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
26 Yu R, Sun T, Zhang X, Li Z, Xu Y, Liu K, Shi Y, Wu X, Shao Y, Kong L. TP53 Co-Mutational Features and NGS-Calibrated Immunohistochemistry Threshold in Gastric Cancer. Onco Targets Ther 2021;14:4967-78. [PMID: 34629881 DOI: 10.2147/OTT.S321949] [Reference Citation Analysis]
27 Andrikopoulou A, Terpos E, Chatzinikolaou S, Apostolidou K, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA, Zagouri F. TP53 mutations determined by targeted NGS in breast cancer: a case-control study. Oncotarget 2021;12:2206-14. [PMID: 34676052 DOI: 10.18632/oncotarget.28071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Joshi P, Basso B, Wang H, Hong SH, Giardina C, Shin DG. rPAC: Route based pathway analysis for cohorts of gene expression data sets. Methods 2021:S1046-2023(21)00227-9. [PMID: 34628030 DOI: 10.1016/j.ymeth.2021.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
29 Saleh MM, Scheffler M, Merkelbach-Bruse S, Scheel AH, Ulmer B, Wolf J, Buettner R. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC. J Thorac Oncol 2021:S1556-0864(21)03187-7. [PMID: 34601169 DOI: 10.1016/j.jtho.2021.08.764] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
30 Guo J, Zhu Y, Yu L, Li Y, Guo J, Cai J, Liu L, Wang Z. Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer. PeerJ 2021;9:e11591. [PMID: 34414020 DOI: 10.7717/peerj.11591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
31 Takács K, Grolmusz V. On the border of the amyloidogenic sequences: prefix analysis of the parallel beta sheets in the PDB_Amyloid collection. J Integr Bioinform 2021. [PMID: 34303324 DOI: 10.1515/jib-2020-0043] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Surien O, Ghazali AR, Masre SF. Chemopreventive effects of pterostilbene through p53 and cell cycle in mouse lung of squamous cell carcinoma model. Sci Rep 2021;11:14862. [PMID: 34290382 DOI: 10.1038/s41598-021-94508-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Smith JC, Sheltzer JM. Genome-wide identification and analysis of prognostic features in human cancers.. [DOI: 10.1101/2021.06.01.446243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Chen L, Mu W, Gu J, Xiao M, Huang L, Zheng M, Li C, Xiao Y, Zhou J, Long X. TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy. Diagnostics (Basel) 2021;11:844. [PMID: 34066756 DOI: 10.3390/diagnostics11050844] [Reference Citation Analysis]
35 Benzerdjeb N, Tantot J, Blanchet C, Philouze P, Mekki Y, Lopez J, Devouassoux-Shisheboran M. Oropharyngeal squamous cell carcinoma: p16/p53 immunohistochemistry as a strong predictor of HPV tumour status. Histopathology 2021;79:381-90. [PMID: 33560536 DOI: 10.1111/his.14350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
36 Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer 2021;1876:188556. [PMID: 33932560 DOI: 10.1016/j.bbcan.2021.188556] [Cited by in Crossref: 45] [Cited by in F6Publishing: 53] [Article Influence: 45.0] [Reference Citation Analysis]
37 Kara A, Özgür A, Nalbantoğlu S, Karadağ A. DNA repair pathways and their roles in drug resistance for lung adenocarcinoma. Mol Biol Rep 2021;48:3813-25. [PMID: 33856604 DOI: 10.1007/s11033-021-06314-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Gbadegesin MA, Omotoso OE, Oluwasola TAO, Okolo CA, Soremekun O, Ogun GO, Oluwasola AO, Odunola OA. Mutational analysis of p53 gene in cervical cancer and useful polymorphic variants in exons 3 and 4. Egypt J Med Hum Genet 2021;22. [DOI: 10.1186/s43042-021-00144-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Li WJ, Wang Y, Liu R, Kasinski AL, Shen H, Slack FJ, Tang DG. MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic. Front Cell Dev Biol 2021;9:640587. [PMID: 33763422 DOI: 10.3389/fcell.2021.640587] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 21.0] [Reference Citation Analysis]
40 Marzano F, Caratozzolo MF, Pesole G, Sbisà E, Tullo A. TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance. Biomedicines 2021;9:241. [PMID: 33673719 DOI: 10.3390/biomedicines9030241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 Xie X, Wang Y, Zhang S, Li J, Yu Z, Ding X, Ye L, Gong P, Zhu Q, Li J, Chen Z, Yao X, Du Z, Zeng Q, Chen H, Yang Z, Chen G. A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma. Aging (Albany NY) 2021;13:2959-81. [PMID: 33472169 DOI: 10.18632/aging.202446] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
42 Ghatak D, Das Ghosh D, Roychoudhury S. Cancer Stemness: p53 at the Wheel. Front Oncol 2020;10:604124. [PMID: 33505918 DOI: 10.3389/fonc.2020.604124] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
43 Wadhwa R, Paudel KR, Shukla S, Shastri M, Gupta G, Devkota HP, Bebawy M, Chellappan DK, Hansbro PM, Dua K. Epigenetic Therapy as a Potential Approach for Targeting Oxidative Stress–Induced Non-Small-Cell Lung Cancer. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects 2021. [DOI: 10.1007/978-981-15-4501-6_106-1] [Reference Citation Analysis]
44 Ghedira K, Kouidhi S, Hamdi Y, Othman H, Kechaou S, Znaidi S, Haïtham S, Rabhi I. Pathway Maps of Orphan and Complex Diseases Using an Integrative Computational Approach. Biomed Res Int 2020;2020:4280467. [PMID: 33376724 DOI: 10.1155/2020/4280467] [Reference Citation Analysis]
45 Koike C, Okudela K, Matsumura M, Mitsui H, Suzuki T, Arai H, Kataoka T, Ishikawa Y, Umeda S, Tateishi Y, Ohashi K. Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma. Histol Histopathol 2021;36:305-15. [PMID: 33368138 DOI: 10.14670/HH-18-294] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Kumar RJ, Chao HX, Simpson DA, Feng W, Cho MG, Roberts VR, Sullivan AR, Shah SJ, Wozny AS, Fagan-Solis K, Kumar S, Luthman A, Ramsden DA, Purvis JE, Gupta GP. Dual inhibition of DNA-PK and DNA polymerase theta overcomes radiation resistance induced by p53 deficiency. NAR Cancer 2020;2:zcaa038. [PMID: 33385162 DOI: 10.1093/narcan/zcaa038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
47 Yoon SJ, Son HY, Shim JK, Moon JH, Kim EH, Chang JH, Teo WY, Kim SH, Park SW, Huh YM, Kang SG. Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres. J Transl Med 2020;18:482. [PMID: 33317554 DOI: 10.1186/s12967-020-02647-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Han C, Yu T, Qin W, Liao X, Huang J, Liu Z, Yu L, Liu X, Chen Z, Yang C, Wang X, Mo S, Zhu G, Su H, Li J, Qin X, Gui Y, Mo Z, Li L, Peng T. Genome-wide association study of the TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and infection with hepatitis B virus. J Gastrointest Oncol 2020;11:1333-49. [PMID: 33457005 DOI: 10.21037/jgo-20-510] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Dalal S, Petersen J, Jhala D. Liquid Biopsies in a Veteran Patient Population With Advanced Prostate and Lung Non-Small Cell Carcinomas: A New Paradigm and Unique Challenge in Personalized Medicine. Fed Pract 2021;38:8-14. [PMID: 33574643 DOI: 10.12788/fp.0065] [Reference Citation Analysis]
50 Fojo T, Huff L, Litman T, Im K, Edgerly M, Del Rivero J, Pittaluga S, Merino M, Bates SE, Dean M. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape. BMC Med Genomics 2020;13:165. [PMID: 33148256 DOI: 10.1186/s12920-020-00809-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
51 Hung YP, Diaz-Perez JA, Cote GM, Wejde J, Schwab JH, Nardi V, Chebib IA, Deshpande V, Selig MK, Bredella MA, Rosenberg AE, Nielsen GP. Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis. Am J Surg Pathol 2020;44:1213-23. [PMID: 32427623 DOI: 10.1097/PAS.0000000000001501] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
52 Chari NS, Ivan C, Le X, Li J, Mijiti A, Patel AA, Osman AA, Peterson CB, Williams MD, Pickering CR, Caulin C, Myers JN, Calin GA, Lai SY. Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. J Natl Cancer Inst 2020;112:266-77. [PMID: 31124563 DOI: 10.1093/jnci/djz097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Mota A, S Oltra S, Moreno-Bueno G. Insight updating of the molecular hallmarks in ovarian carcinoma. EJC Suppl 2020;15:16-26. [PMID: 33240439 DOI: 10.1016/j.ejcsup.2019.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
54 Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, Li X, Babur O, Hsu TK, Lichtarge O, Weinstein JN, Akbani R, Wheeler DA. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep 2019;28:1370-1384.e5. [PMID: 31365877 DOI: 10.1016/j.celrep.2019.07.001] [Cited by in Crossref: 196] [Cited by in F6Publishing: 210] [Article Influence: 98.0] [Reference Citation Analysis]
55 Han C, Yu T, Qin W, Liao X, Huang J, Liu Z, Yu L, Liu X, Chen Z, Yang C, Wang X, Mo S, Zhu G, Su H, Mo Z, Peng T. Genome-wide association study of TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and hepatitis B virus infection in Guangxi.. [DOI: 10.1101/2020.08.03.235135] [Reference Citation Analysis]
56 Astolfi A, Nannini M, Indio V, Schipani A, Rizzo A, Perrone AM, De Iaco P, Pirini MG, De Leo A, Urbini M, Secchiero P, Pantaleo MA. Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. Cancers (Basel) 2020;12:E2126. [PMID: 32751892 DOI: 10.3390/cancers12082126] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
57 Zaidi SH, Harrison TA, Phipps AI, Steinfelder R, Trinh QM, Qu C, Banbury BL, Georgeson P, Grasso CS, Giannakis M, Adams JB, Alwers E, Amitay EL, Barfield RT, Berndt SI, Borozan I, Brenner H, Brezina S, Buchanan DD, Cao Y, Chan AT, Chang-Claude J, Connolly CM, Drew DA, Farris AB 3rd, Figueiredo JC, French AJ, Fuchs CS, Garraway LA, Gruber S, Guinter MA, Hamilton SR, Harlid S, Heisler LE, Hidaka A, Hopper JL, Huang WY, Huyghe JR, Jenkins MA, Krzyzanowski PM, Lemire M, Lin Y, Luo X, Mardis ER, McPherson JD, Miller JK, Moreno V, Mu XJ, Nishihara R, Papadopoulos N, Pasternack D, Quist MJ, Rafikova A, Reid EEG, Shinbrot E, Shirts BH, Stein LD, Teney CD, Timms L, Um CY, Van Guelpen B, Van Tassel M, Wang X, Wheeler DA, Yung CK, Hsu L, Ogino S, Gsur A, Newcomb PA, Gallinger S, Hoffmeister M, Campbell PT, Thibodeau SN, Sun W, Hudson TJ, Peters U. Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nat Commun 2020;11:3644. [PMID: 32686686 DOI: 10.1038/s41467-020-17386-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
58 Grosser B, Kohlruss M, Slotta-Huspenina J, Jesinghaus M, Pfarr N, Steiger K, Novotny A, Gaida MM, Schmidt T, Hapfelmeier A, Ott K, Weichert W, Keller G. Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer. Cancers (Basel) 2020;12:E1689. [PMID: 32630478 DOI: 10.3390/cancers12061689] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
59 Saha G, Singh R, Mandal A, Das S, Chattopadhyay E, Panja P, Roy P, DeSarkar N, Gulati S, Ghatak S, Ghosh S, Banerjee S, Roy B, Ghosh S, Chaudhuri D, Arora N, Biswas NK, Sikdar N. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients. Mol Med 2020;26:59. [PMID: 32552660 DOI: 10.1186/s10020-020-00183-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
60 Cheteh EH, Sarne V, Ceder S, Bianchi J, Augsten M, Rundqvist H, Egevad L, Östman A, Wiman KG. Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discov 2020;6:42. [PMID: 32528731 DOI: 10.1038/s41420-020-0272-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 16.5] [Reference Citation Analysis]
61 Patel RR, Ramkissoon SH, Ross J, Weintraub L. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors. Pediatr Blood Cancer 2020;67:e28338. [PMID: 32386112 DOI: 10.1002/pbc.28338] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
62 Bieg-Bourne CC, Okamura R, Kurzrock R. Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden. Mol Oncol 2020;14:1242-51. [PMID: 32187847 DOI: 10.1002/1878-0261.12672] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
63 Kumar RJ, Chao HX, Roberts VR, Sullivan AR, Shah SJ, Simpson DA, Feng W, Wozny A, Kumar S, Purvis JE, Gupta GP. Hyperactive end joining repair mediates resistance to DNA damaging therapy in p53-deficient cells.. [DOI: 10.1101/2020.04.01.021253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Orr BA, Clay MR, Pinto EM, Kesserwan C. An update on the central nervous system manifestations of Li-Fraumeni syndrome. Acta Neuropathol 2020;139:669-87. [PMID: 31468188 DOI: 10.1007/s00401-019-02055-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 18.0] [Reference Citation Analysis]
65 Ziaran S, Harsanyi S, Bevizova K, Varchulova Novakova Z, Trebaticky B, Bujdak P, Galbavy S, Danisovic L. Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence. Eur J Histochem 2020;64. [PMID: 32214283 DOI: 10.4081/ejh.2020.3098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
66 Veß A, Hollemann T. Methylglyoxal induces nuclear accumulation of p53 and γH2AX in normal and cancer cells.. [DOI: 10.1101/2020.03.19.998773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Benedetti F, Cocchi F, Latinovic OS, Curreli S, Krishnan S, Munawwar A, Gallo RC, Zella D. Role of Mycoplasma Chaperone DnaK in Cellular Transformation. Int J Mol Sci 2020;21:E1311. [PMID: 32075244 DOI: 10.3390/ijms21041311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
68 Shahbandi A, Nguyen HD, Jackson JG. TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. Trends Cancer 2020;6:98-110. [PMID: 32061310 DOI: 10.1016/j.trecan.2020.01.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
69 Wang C, Huang W, Lin J, Fang F, Wang X, Wang H. Triclosan-induced liver and brain injury in zebrafish (Danio rerio) via abnormal expression of miR-125 regulated by PKCα/Nrf2/p53 signaling pathways. Chemosphere 2020;241:125086. [DOI: 10.1016/j.chemosphere.2019.125086] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
70 Olafson LR, Gunawardena M, Nixdorf S, McDonald KL, Rapkins RW. The role of TP53 gain-of-function mutation in multifocal glioblastoma. J Neurooncol 2020;147:37-47. [PMID: 32002804 DOI: 10.1007/s11060-019-03318-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
71 Liao X, Vavinskaya V, Sun K, Hao Y, Li X, Valasek M, Xu R, Polydorides AD, Houldsworth J, Harpaz N. Mutation profile of high-grade appendiceal mucinous neoplasm. Histopathology 2020;76:461-9. [PMID: 31491041 DOI: 10.1111/his.13986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
72 Tang Q, Su Z, Gu W, Rustgi AK. Mutant p53 on the Path to Metastasis. Trends Cancer 2020;6:62-73. [PMID: 31952783 DOI: 10.1016/j.trecan.2019.11.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 14.7] [Reference Citation Analysis]
73 Zhang P, Kitchen-smith I, Xiong L, Stracquadanio G, Brown K, Richter P, Wallace M, Bond E, Sahgal N, Moore S, Nornes S, De Val S, Surakhy M, Sims D, Wang X, Bell DA, Zeron-medina J, Jiang Y, Ryan A, Selfe J, Shipley J, Kar S, Pharoah P, Loveday C, Jansen R, Grochola LF, Palles C, Protheroe A, Millar V, Ebner D, Pagadala M, Blagden SP, Maughan T, Domingo E, Tomlinson I, Turnbull C, Carter H, Bond G. Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response.. [DOI: 10.1101/835918] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Al-Alem LF, Baker AT, Pandya UM, Eisenhauer EL, Rueda BR. Understanding and Targeting Apoptotic Pathways in Ovarian Cancer. Cancers (Basel) 2019;11:E1631. [PMID: 31652965 DOI: 10.3390/cancers11111631] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
75 Behring M, Vazquez AI, Cui X, Irvin MR, Ojesina AI, Agarwal S, Manne U, Shrestha S. Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages. Mol Genet Genomic Med 2019;7:e1001. [PMID: 31637877 DOI: 10.1002/mgg3.1001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
76 Lucchesi C, Khalifa E, Laizet Y, Soubeyran I, Mathoulin-Pelissier S, Chomienne C, Italiano A. Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy. JAMA Oncol. 2018;4:1398-1404. [PMID: 29801054 DOI: 10.1001/jamaoncol.2018.0723] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 16.0] [Reference Citation Analysis]
77 Barbosa K, Li S, Adams PD, Deshpande AJ. The role of TP53 in acute myeloid leukemia: Challenges and opportunities. Genes Chromosomes Cancer 2019;58:875-88. [DOI: 10.1002/gcc.22796] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]
78 Zhang Y, Xu L, Chang Y, Li Y, Butler W, Jin E, Wang A, Tao Y, Chen X, Liang C, Huang J. Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. Prostate Cancer Prostatic Dis 2020;23:160-71. [PMID: 31471556 DOI: 10.1038/s41391-019-0172-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
79 Zhang W, Flemington EK, Zhang K. Driver gene mutations based clustering of tumors: methods and applications. Bioinformatics 2018;34:i404-11. [PMID: 29950003 DOI: 10.1093/bioinformatics/bty232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Xande JG, Dias AP, Tamura RE, Cruz MC, Brito B, Ferreira RA, Strauss BE, Costanzi-Strauss E. Bicistronic transfer of CDKN2A and p53 culminates in collaborative killing of human lung cancer cells in vitro and in vivo. Gene Ther 2020;27:51-61. [PMID: 31439890 DOI: 10.1038/s41434-019-0096-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
81 Rodriguez-Ramirez C, Nör JE. p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy. Crit Rev Oncog 2018;23:173-87. [PMID: 30311573 DOI: 10.1615/CritRevOncog.2018027353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
82 Hassan FU, Rehman MS, Khan MS, Ali MA, Javed A, Nawaz A, Yang C. Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects. Front Genet 2019;10:514. [PMID: 31214247 DOI: 10.3389/fgene.2019.00514] [Cited by in Crossref: 132] [Cited by in F6Publishing: 138] [Article Influence: 44.0] [Reference Citation Analysis]
83 Wang X, Bai Y, Han Y, Meng J, Liu H. Downregulation of GBAS regulates oral squamous cell carcinoma proliferation and apoptosis via the p53 signaling pathway. Onco Targets Ther 2019;12:3729-42. [PMID: 31190874 DOI: 10.2147/OTT.S207930] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
84 Lin CS, Huang YY, Pan SC, Cheng CT, Liu CC, Shih CH, Ho HL, Yeh YC, Chou TY, Lee MY, Wei YH. Involvement of increased p53 expression in the decrease of mitochondrial DNA copy number and increase of SUVmax of FDG-PET scan in esophageal squamous cell carcinoma. Mitochondrion 2019;47:54-63. [PMID: 31071450 DOI: 10.1016/j.mito.2019.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
85 Christopoulos P, Budczies J, Kirchner M, Dietz S, Sültmann H, Thomas M, Stenzinger A. Defining molecular risk in ALK+ NSCLC. Oncotarget 2019;10:3093-103. [PMID: 31139322 DOI: 10.18632/oncotarget.26886] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
86 Pereira SS, Monteiro MP, Antonini SR, Pignatelli D. Apoptosis regulation in adrenocortical carcinoma. Endocr Connect 2019;8:R91-R104. [PMID: 30978697 DOI: 10.1530/EC-19-0114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
87 Biswas NK, Das C, Das S, Maitra A, Nair S, Gupta T, D'Cruz AK, Sarin R, Majumder PP. Lymph node metastasis in oral cancer is strongly associated with chromosomal instability and DNA repair defects. Int J Cancer 2019;145:2568-79. [PMID: 30924133 DOI: 10.1002/ijc.32305] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
88 Talib WH, Al-Hadid SA, Ali MBW, Al-Yasari IH, Ali MRA. Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action. Breast Cancer (Dove Med Press) 2018;10:207-17. [PMID: 30568488 DOI: 10.2147/BCTT.S167812] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
89 Echchannaoui H, Petschenka J, Ferreira EA, Hauptrock B, Lotz-Jenne C, Voss RH, Theobald M. A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo. Mol Ther 2019;27:261-71. [PMID: 30528087 DOI: 10.1016/j.ymthe.2018.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
90 Qin N, Han F, Li L, Ge Y, Lin W, Wang J, Wu L, Zhao G, Deng Y, Zhang J. Deubiquitinating enzyme 4 facilitates chemoresistance in glioblastoma by inhibiting P53 activity. Oncol Lett 2019;17:958-64. [PMID: 30655854 DOI: 10.3892/ol.2018.9654] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
91 Christopoulos P, Kirchner M, Bozorgmehr F, Endris V, Elsayed M, Budczies J, Ristau J, Penzel R, Herth F, Heussel C, Eichhorn M, Muley T, Meister M, Fischer J, Rieken S, Lasitschka F, Bischoff H, Sotillo R, Schirmacher P, Thomas M, Stenzinger A. Identification of a highly lethal V3 + TP53 + subset in ALK + lung adenocarcinoma: Identification of a highly lethal V3+ TP53 + subset in ALK+ NSCLC. Int J Cancer 2019;144:190-9. [DOI: 10.1002/ijc.31893] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 10.5] [Reference Citation Analysis]
92 Raimondi F, Russell RB. Studying how genetic variants affect mechanism in biological systems. Essays Biochem 2018;62:575-82. [PMID: 30315099 DOI: 10.1042/EBC20180021] [Reference Citation Analysis]
93 Barnes JL, Zubair M, John K, Poirier MC, Martin FL. Carcinogens and DNA damage. Biochem Soc Trans. 2018;46:1213-1224. [PMID: 30287511 DOI: 10.1042/bst20180519] [Cited by in Crossref: 129] [Cited by in F6Publishing: 139] [Article Influence: 32.3] [Reference Citation Analysis]
94 Greathouse KL, White JR, Vargas AJ, Bliskovsky VV, Beck JA, von Muhlinen N, Polley EC, Bowman ED, Khan MA, Robles AI, Cooks T, Ryan BM, Padgett N, Dzutsev AH, Trinchieri G, Pineda MA, Bilke S, Meltzer PS, Hokenstad AN, Stickrod TM, Walther-Antonio MR, Earl JP, Mell JC, Krol JE, Balashov SV, Bhat AS, Ehrlich GD, Valm A, Deming C, Conlan S, Oh J, Segre JA, Harris CC. Interaction between the microbiome and TP53 in human lung cancer. Genome Biol 2018;19:123. [PMID: 30143034 DOI: 10.1186/s13059-018-1501-6] [Cited by in Crossref: 136] [Cited by in F6Publishing: 148] [Article Influence: 34.0] [Reference Citation Analysis]
95 Fischer NW, Prodeus A, Gariépy J. Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity. JCI Insight 2018;3:121364. [PMID: 30089713 DOI: 10.1172/jci.insight.121364] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
96 Chow MJ, Babak MV, Tan KW, Cheong MC, Pastorin G, Gaiddon C, Ang WH. Induction of the Endoplasmic Reticulum Stress Pathway by Highly Cytotoxic Organoruthenium Schiff-Base Complexes. Mol Pharm 2018;15:3020-31. [PMID: 29979603 DOI: 10.1021/acs.molpharmaceut.8b00003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
97 Cuceu C, Colicchio B, Jeandidier E, Junker S, Plassa F, Shim G, Mika J, Frenzel M, Al Jawhari M, Hempel WM, O'Brien G, Lenain A, Morat L, Girinsky T, Dieterlen A, Polanska J, Badie C, Carde P, M'Kacher R. Independent Mechanisms Lead to Genomic Instability in Hodgkin Lymphoma: Microsatellite or Chromosomal Instability . Cancers (Basel) 2018;10:E233. [PMID: 30011886 DOI: 10.3390/cancers10070233] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
98 Noda M, Okayama H, Kofunato Y, Chida S, Saito K, Tada T, Ashizawa M, Nakajima T, Aoto K, Kikuchi T, Sakamoto W, Endo H, Fujita S, Saito M, Momma T, Ohki S, Kono K. Prognostic role of FUT8 expression in relation to p53 status in stage II and III colorectal cancer. PLoS One 2018;13:e0200315. [PMID: 29975776 DOI: 10.1371/journal.pone.0200315] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
99 Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, Uras IZ, Höllein A, Neuberg DS, Ebert BL, Ringler A, Mueller AC, Loizou JI, Hinds PW, Vogl C, Heller G, Kubicek S, Zuber J, Malumbres M, Farlik M, Villunger A, Kollmann K, Sexl V. CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. Cancer Discov 2018;8:884-97. [PMID: 29899063 DOI: 10.1158/2159-8290.CD-17-0912] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 10.8] [Reference Citation Analysis]
100 Shumilov E, Flach J, Pabst T, Fiedler M, Angelillo-scherrer A, Trümper L, Joncourt R, Kohlmann A, Bacher U. Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. Critical Reviews in Oncology/Hematology 2018;126:64-79. [DOI: 10.1016/j.critrevonc.2018.03.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
101 Toufektchan E, Toledo F. The Guardian of the Genome Revisited: p53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure. Cancers (Basel) 2018;10:E135. [PMID: 29734785 DOI: 10.3390/cancers10050135] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 14.8] [Reference Citation Analysis]
102 Gomes AS, Trovão F, Andrade Pinheiro B, Freire F, Gomes S, Oliveira C, Domingues L, Romão MJ, Saraiva L, Carvalho AL. The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding. Int J Mol Sci 2018;19:E1184. [PMID: 29652801 DOI: 10.3390/ijms19041184] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
103 Zemanova J, Hylse O, Collakova J, Vesely P, Oltova A, Borsky M, Zaprazna K, Kasparkova M, Janovska P, Verner J, Kohoutek J, Dzimkova M, Bryja V, Jaskova Z, Brychtova Y, Paruch K, Trbusek M. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget 2016;7:62091-106. [PMID: 27556692 DOI: 10.18632/oncotarget.11388] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
104 Cuceu C, Hempel WM, Sabatier L, Bosq J, Carde P, M'kacher R. Chromosomal Instability in Hodgkin Lymphoma: An In-Depth Review and Perspectives. Cancers (Basel) 2018;10:E91. [PMID: 29587466 DOI: 10.3390/cancers10040091] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
105 Dominijanni A, Gmeiner WH. Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations. Cancer Drug Resist 2018;1:48-58. [PMID: 30613833 DOI: 10.20517/cdr.2018.01] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
106 Greathouse KL, White JR, Vargas AJ, Bliskovsky VV, Beck JA, Muhlinen NV, Polley EC, Bowman ED, Khan MA, Robles AI, Cooks T, Ryan BM, Dzutsev AH, Trinchieri G, Pineda MA, Bilke S, Meltzer PS, Hokenstad AN, Stickrod TM, Walther-antonio MR, Earl JP, Mell JC, Krol JE, Balashov SV, Bhat AS, Ehrlich GD, Valm A, Deming C, Conlan S, Oh J, Segre JA, Harris CC. Microbiome-TP53 Gene Interaction in Human Lung Cancer.. [DOI: 10.1101/273524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Murnyák B, Hortobágyi T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget 2016;7:64910-20. [PMID: 27626311 DOI: 10.18632/oncotarget.11912] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 16.8] [Reference Citation Analysis]
108 Mandal PK, Biswas S, Mandal G, Purohit S, Gupta A, Majumdar (Giri) A, Roy Chowdhury S, Bhattacharyya A. CCL2 conditionally determines CCL22-dependent Th2-accumulation during TGF-β-induced breast cancer progression. Immunobiology 2018;223:151-61. [DOI: 10.1016/j.imbio.2017.10.031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
109 Hornshøj H, Nielsen MM, Sinnott-Armstrong NA, Świtnicki MP, Juul M, Madsen T, Sallari R, Kellis M, Ørntoft T, Hobolth A, Pedersen JS. Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival. NPJ Genom Med 2018;3:1. [PMID: 29354286 DOI: 10.1038/s41525-017-0040-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
110 Zhang M, Heldin A, Palomar-Siles M, Öhlin S, Bykov VJN, Wiman KG. Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors. Front Oncol 2017;7:323. [PMID: 29354595 DOI: 10.3389/fonc.2017.00323] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
111 Vidotto T, Tiezzi DG, Squire JA. Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer. Mol Cytogenet 2018;11:1. [PMID: 29308088 DOI: 10.1186/s13039-017-0348-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
112 Kamińska I, Bar JK. The association between p53 protein phosphorylation at serine 15, serine 20 and sensitivity of cells isolated from patients with ovarian cancer and cell lines to chemotherapy in in vitro study. Pharmacol Rep 2018;70:570-6. [PMID: 29684847 DOI: 10.1016/j.pharep.2017.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
113 Shimura T, Tada Y, Hirai H, Kawakita D, Kano S, Tsukahara K, Shimizu A, Takase S, Imanishi Y, Ozawa H, Okami K, Sato Y, Sato Y, Fushimi C, Takahashi H, Okada T, Sato H, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Ando M, Kohsaka S, Hanazawa T, Chazono H, Kadokura Y, Kobayashi H, Nagao T. Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas. Oncotarget 2018;9:1852-67. [PMID: 29416736 DOI: 10.18632/oncotarget.22927] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
114 Ko CJ, Glusac EJ, Mcniff JM, Rodic N, Leffell DJ. Squamous proliferations on the legs of women: Qualitative examination of histopathology, TP53 sequencing, and implications for diagnosis in a series of 30 cases. Journal of the American Academy of Dermatology 2017;77:1126-1132.e1. [DOI: 10.1016/j.jaad.2017.04.1119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
115 Andeen NK, Bowman R, Baullinger T, Brooks JM, Tretiakova MS. Epitope Preservation Methods for Tissue Microarrays: Longitudinal Prospective Study. Am J Clin Pathol 2017;148:380-9. [PMID: 29106459 DOI: 10.1093/ajcp/aqx062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
116 Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res 2017;77:1250-60. [PMID: 28254861 DOI: 10.1158/0008-5472.CAN-16-2179] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 9.6] [Reference Citation Analysis]
117 Hornshøj H, Nielsen MM, Sinnott-armstrong NA, Świtnicki MP, Juul M, Madsen T, Sallari R, Kellis M, Ørntoft T, Hobolth A, Pedersen JS. Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival.. [DOI: 10.1101/182642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
118 Yang JC, Risch E, Zhang M, Huang C, Huang H, Lu L. Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival. Future Oncol 2017;13:1981-90. [PMID: 28829218 DOI: 10.2217/fon-2017-0084] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
119 Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S, Doubek M. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia 2018;32:450-61. [PMID: 28744014 DOI: 10.1038/leu.2017.230] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
120 Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC, Petty WJ, Alistar AT, Levine EA, Staren ED, Langefeld CD, Miller V, Singal G, Petro RM, Robinson M, Blackstock W, Powell BL, Wagner LI, Foley KL, Abraham E, Pasche B, Zhang W. Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. Theranostics 2017;7:2914-23. [PMID: 28824725 DOI: 10.7150/thno.20355] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
121 Yotsukura S, Karasuyama M, Takigawa I, Mamitsuka H. Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code. Brief Bioinform 2017;18:619-33. [PMID: 27197545 DOI: 10.1093/bib/bbw040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
122 Le Morvan M, Zinovyev A, Vert JP. NetNorM: Capturing cancer-relevant information in somatic exome mutation data with gene networks for cancer stratification and prognosis. PLoS Comput Biol 2017;13:e1005573. [PMID: 28650955 DOI: 10.1371/journal.pcbi.1005573] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
123 Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood 2017;130:699-712. [PMID: 28607134 DOI: 10.1182/blood-2017-02-763086] [Cited by in Crossref: 94] [Cited by in F6Publishing: 103] [Article Influence: 18.8] [Reference Citation Analysis]
124 Skinner HD, Chen Q, Elimova E, Wadhwa R, Song S, Ajani JA. Predictive Biomarkers for Therapy in Adenocarcinoma of the Upper Digestive Tract. Biomarkers in Cancer Screening and Early Detection 2017. [DOI: 10.1002/9781118468869.ch10] [Reference Citation Analysis]
125 Taylor NJ, Nikolaishvili-Feinberg N, Midkiff BR, Conway K, Millikan RC, Geradts J. Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas. Appl Immunohistochem Mol Morphol 2016;24:398-404. [PMID: 26200835 DOI: 10.1097/PAI.0000000000000207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
126 Andor N, Maley CC, Ji HP. Genomic Instability in Cancer: Teetering on the Limit of Tolerance. Cancer Res 2017;77:2179-85. [PMID: 28432052 DOI: 10.1158/0008-5472.CAN-16-1553] [Cited by in Crossref: 123] [Cited by in F6Publishing: 134] [Article Influence: 24.6] [Reference Citation Analysis]
127 Siebring-van Olst E, Blijlevens M, de Menezes RX, van der Meulen-Muileman IH, Smit EF, van Beusechem VW. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment. Mol Oncol 2017;11:534-51. [PMID: 28296343 DOI: 10.1002/1878-0261.12052] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
128 Chen J, Wang A, Chen Q. SirT3 and p53 Deacetylation in Aging and Cancer: SirT3 DEACETYLATE p53 IN AGING AND CANCER. J Cell Physiol 2017;232:2308-11. [DOI: 10.1002/jcp.25669] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
129 De Smet F, Saiz Rubio M, Hompes D, Naus E, De Baets G, Langenberg T, Hipp MS, Houben B, Claes F, Charbonneau S, Delgado Blanco J, Plaisance S, Ramkissoon S, Ramkissoon L, Simons C, van den Brandt P, Weijenberg M, Van England M, Lambrechts S, Amant F, D'Hoore A, Ligon KL, Sagaert X, Schymkowitz J, Rousseau F. Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. J Pathol 2017;242:24-38. [PMID: 28035683 DOI: 10.1002/path.4872] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
130 Cheok CF, Lane DP. Exploiting the p53 Pathway for Therapy. Cold Spring Harb Perspect Med 2017;7:a026310. [PMID: 28193768 DOI: 10.1101/cshperspect.a026310] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
131 Zhang W, Edwards A, Flemington EK, Zhang K. Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers. Cancer Inform 2017;16:1176935117691267. [PMID: 28469388 DOI: 10.1177/1176935117691267] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
132 Alvarez-cubero MJ, Martinez-gonzalez LJ, Robles-fernandez I, Martinez-herrera J, Garcia-rodriguez G, Pascual-geler M, Cozar JM, Lorente JA. Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine. Mol Diagn Ther 2017;21:167-78. [DOI: 10.1007/s40291-016-0248-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
133 Fernandez-pol S, Ma L, Ohgami RS, Arber DA. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol 2017;30:382-92. [DOI: 10.1038/modpathol.2016.206] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
134 Hainaut P, Pfeifer GP. Somatic TP53 Mutations in the Era of Genome Sequencing. Cold Spring Harb Perspect Med 2016;6:a026179. [PMID: 27503997 DOI: 10.1101/cshperspect.a026179] [Cited by in Crossref: 118] [Cited by in F6Publishing: 127] [Article Influence: 19.7] [Reference Citation Analysis]
135 Park S, Lee J, Kim YH, Park J, Shin JW, Nam S. Clinical relevance and molecular phenotypes in gastric cancer, of TP53 mutations and gene expressions, in combination with other gene mutations. Sci Rep. 2016;6:34822. [PMID: 27708434 DOI: 10.1038/srep34822] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
136 Robles AI, Jen J, Harris CC. Clinical Outcomes of TP53 Mutations in Cancers. Cold Spring Harb Perspect Med 2016;6:a026294. [PMID: 27449973 DOI: 10.1101/cshperspect.a026294] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
137 Te Raa GD, Kater AP. TP53 dysfunction in CLL: Implications for prognosis and treatment. Best Pract Res Clin Haematol 2016;29:90-9. [PMID: 27742075 DOI: 10.1016/j.beha.2016.08.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
138 Zhang W, Edwards A, Fang Z, Flemington EK, Zhang K. Integrative Genomics and Transcriptomics Analysis Reveals Potential Mechanisms for Favorable Prognosis of Patients with HPV-Positive Head and Neck Carcinomas. Sci Rep 2016;6:24927. [PMID: 27108969 DOI: 10.1038/srep24927] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
139 Henrique T, José Freitas da Silveira N, Henrique Cunha Volpato A, Mioto MM, Carolina Buzzo Stefanini A, Bachir Fares A, Gustavo da Silva Castro Andrade J, Masson C, Verónica Mendoza López R, Daumas Nunes F, Paulo Kowalski L, Severino P, Tajara EH. HNdb: an integrated database of gene and protein information on head and neck squamous cell carcinoma. Database (Oxford) 2016;2016:baw026. [PMID: 27013077 DOI: 10.1093/database/baw026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
140 Ma X, Le Teuff G, Lacas B, Tsao MS, Graziano S, Pignon JP, Douillard JY, Le Chevalier T, Seymour L, Filipits M, Pirker R, Jänne PA, Shepherd FA, Brambilla E, Soria JC, Hainaut P; LACE-Bio Collaborative Group. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. J Thorac Oncol 2016;11:850-61. [PMID: 26899019 DOI: 10.1016/j.jtho.2016.02.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 62] [Article Influence: 9.2] [Reference Citation Analysis]
141 Velletri T, Xie N, Wang Y, Huang Y, Yang Q, Chen X, Chen Q, Shou P, Gan Y, Cao G, Melino G, Shi Y. P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development. Cell Death Dis 2016;7:e2015. [PMID: 26775693 DOI: 10.1038/cddis.2015.367] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 8.2] [Reference Citation Analysis]
142 Wei N, Chu E, Wu SY, Wipf P, Schmitz JC. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells. Oncotarget 2015;6:4745-56. [PMID: 25544765 DOI: 10.18632/oncotarget.2938] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
143 [DOI: 10.1109/icacsis.2015.7415177] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
144 Ochs-Balcom HM, Marian C, Nie J, Brasky TM, Goerlitz DS, Trevisan M, Edge SB, Winston J, Berry DL, Kallakury BV, Freudenheim JL, Shields PG. Adiposity is associated with p53 gene mutations in breast cancer. Breast Cancer Res Treat 2015;153:635-45. [PMID: 26364297 DOI: 10.1007/s10549-015-3570-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
145 Caratozzolo MF, Valletti A, Gigante M, Aiello I, Mastropasqua F, Marzano F, Ditonno P, Carrieri G, Simonnet H, D'Erchia AM, Ranieri E, Pesole G, Sbisà E, Tullo A. TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma. Oncotarget 2014;5:7446-57. [PMID: 25277184 DOI: 10.18632/oncotarget.2081] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
146 Bally C, Renneville A, Preudhomme C, Legrand M, Adès L, de Thé H, Fenaux P, Lehmann-Che J. Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes. Leuk Res 2015:S0145-2126(15)30344-1. [PMID: 26271412 DOI: 10.1016/j.leukres.2015.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
147 Karchin R, Cline MS. Human genetics special issue on computational molecular medicine. Hum Genet 2015;134:455-7. [PMID: 25805167 DOI: 10.1007/s00439-015-1545-6] [Reference Citation Analysis]
148 Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, Hallberg A, Bykov VJ, Björklund U, Wiman KG. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis 2015;6:e1794. [PMID: 26086967 DOI: 10.1038/cddis.2015.143] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, Hallberg A, Bykov VJ, Björklund U, Wiman KG. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis 2015;6:e1794. [PMID: 26086967 DOI: 10.1038/cddis.2015.143] [Cited by in Crossref: 116] [Cited by in F6Publishing: 129] [Article Influence: 16.6] [Reference Citation Analysis]
150 Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, Hallberg A, Bykov VJ, Björklund U, Wiman KG. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis 2015;6:e1794. [PMID: 26086967 DOI: 10.1038/cddis.2015.143] [Reference Citation Analysis]
151 Pan P, Van Emon J. Application in Pesticide Analysis: Liquid Chromatography—A Review of the State of Science for Biomarker Discovery and Identification. High Performance Liquid Chromatography in Pesticide Residue Analysis 2015. [DOI: 10.1201/b18481-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
152 Verner J, Trbusek M, Chovancova J, Jaskova Z, Moulis M, Folber F, Halouzka R, Mayer J, Pospisilova S, Doubek M. NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines. Leuk Lymphoma 2015;56:3198-206. [PMID: 25827173 DOI: 10.3109/10428194.2015.1034701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
153 Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget 2014;5:3871-9. [PMID: 25003695 DOI: 10.18632/oncotarget.2004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
154 Yin H, Zhao F, Zhang D, Li J. Hyaluronic acid conjugated β-cyclodextrin-oligoethylenimine star polymer for CD44-targeted gene delivery. International Journal of Pharmaceutics 2015;483:169-79. [DOI: 10.1016/j.ijpharm.2015.02.022] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
155 Cooks T, Harris CC. p53 mutations and inflammation-associated cancer are linked through TNF signaling. Mol Cell 2014;56:611-2. [PMID: 25479634 DOI: 10.1016/j.molcel.2014.11.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
156 Applications of comprehensive cancer progression models in the fight against cancer. Systems Biology of Cancer 2015. [DOI: 10.1017/cbo9780511979811.030] [Reference Citation Analysis]
157 Katz S, El-deiry WS. Prognosis of cancer. Systems Biology of Cancer 2015. [DOI: 10.1017/cbo9780511979811.032] [Reference Citation Analysis]
158 Gulley ML. Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. Exp Mol Med. 2015;47:e134. [PMID: 25613731 DOI: 10.1038/emm.2014.93] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
159 Netter J, Lehmann-Che J, Lambert J, Tallet A, Lourenco N, Soliman H, Bertheau P, Pariente B, Chirica M, Pocard M, Allez M, De The H, Gornet JM. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer. Bull Cancer 2015;102:117-25. [PMID: 25609485 DOI: 10.1016/j.bulcan.2014.12.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
160 Colombara DV, Eidsmoe D, Stern JE, Feng Q, Vesselle H, Hawes SE. No Association between p53 Immunohistochemical Staining and RASSF1 or DAPK1 Hypermethylation in Non-Small Cell Lung Cancer. JCT 2015;06:631-637. [DOI: 10.4236/jct.2015.68069] [Reference Citation Analysis]
161 Sammons MA, Zhu J, Drake AM, Berger SL. TP53 engagement with the genome occurs in distinct local chromatin environments via pioneer factor activity. Genome Res 2015;25:179-88. [PMID: 25391375 DOI: 10.1101/gr.181883.114] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 10.1] [Reference Citation Analysis]
162 Murao K, Yoshioka R, Kubo Y. Human papillomavirus infection in Bowen disease: Negative p53 expression, not p16 INK4a overexpression, is correlated with human papillomavirus-associated Bowen disease. J Dermatol 2014;41:878-84. [DOI: 10.1111/1346-8138.12613] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
163 Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Hum Genet 2015;134:497-507. [PMID: 25108461 DOI: 10.1007/s00439-014-1470-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
164 Bouchalova P, Nenutil R, Muller P, Hrstka R, Appleyard MV, Murray K, Jordan LB, Purdie CA, Quinlan P, Thompson AM, Vojtesek B, Coates PJ. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. J Pathol 2014;233:238-46. [PMID: 24687952 DOI: 10.1002/path.4356] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
165 Larson C, Mendez N, Reid T. Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system. Mol Ther 2013;21:922-3. [PMID: 23636291 DOI: 10.1038/mt.2013.76] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
166 Otsubo C, Otomo R, Miyazaki M, Matsushima-Hibiya Y, Kohno T, Iwakawa R, Takeshita F, Okayama H, Ichikawa H, Saya H, Kiyono T, Ochiya T, Tashiro F, Nakagama H, Yokota J, Enari M. TSPAN2 is involved in cell invasion and motility during lung cancer progression. Cell Rep 2014;7:527-38. [PMID: 24726368 DOI: 10.1016/j.celrep.2014.03.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
167 Bisio A, Ciribilli Y, Fronza G, Inga A, Monti P. TP53 Mutants in the Tower of Babel of Cancer Progression. Human Mutation 2014;35:689-701. [DOI: 10.1002/humu.22514] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
168 Gillet E, Alentorn A, Doukouré B, Mundwiller E, van Thuijl HF, Reijneveld JC, Medina JA, Liou A, Marie Y, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Idbaih A. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. J Neurooncol 2014;118:131-9. [PMID: 24590827 DOI: 10.1007/s11060-014-1407-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
169 Trbusek M, Malcikova J. TP53 aberrations in chronic lymphocytic leukemia. Adv Exp Med Biol 2013;792:109-31. [PMID: 24014294 DOI: 10.1007/978-1-4614-8051-8_5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
170 Read ML, Seed RI, Fong JC, Modasia B, Ryan GA, Watkins RJ, Gagliano T, Smith VE, Stratford AL, Kwan PK, Sharma N, Dixon OM, Watkinson JC, Boelaert K, Franklyn JA, Turnell AS, McCabe CJ. The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. Endocrinology 2014;155:1222-34. [PMID: 24506068 DOI: 10.1210/en.2013-1646] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
171 Malcikova J, Pavlova S, Kozubik KS, Pospisilova S. TP53 Mutation Analysis in Clinical Practice: Lessons From Chronic Lymphocytic Leukemia. Human Mutation 2014;35:663-71. [DOI: 10.1002/humu.22508] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
172 Siddik ZH. Apoptosis in Cancer. Cancer Drug Design and Discovery 2014. [DOI: 10.1016/b978-0-12-396521-9.00012-7] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
173 Liu Y, Zhang Y. Nucleolar Signaling Determines Cell Fate: The RP-Mdm2-p53 Axis Fine-Tunes Cellular Homeostasis. Nuclear Signaling Pathways and Targeting Transcription in Cancer 2014. [DOI: 10.1007/978-1-4614-8039-6_9] [Reference Citation Analysis]
174 Checler F, Alves da Costa C. p53 in neurodegenerative diseases and brain cancers. Pharmacol Ther 2014;142:99-113. [PMID: 24287312 DOI: 10.1016/j.pharmthera.2013.11.009] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 7.2] [Reference Citation Analysis]
175 Bursac S, Brdovcak MC, Donati G, Volarevic S. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. Biochim Biophys Acta 2014;1842:817-30. [PMID: 24514102 DOI: 10.1016/j.bbadis.2013.08.014] [Cited by in Crossref: 108] [Cited by in F6Publishing: 114] [Article Influence: 12.0] [Reference Citation Analysis]
176 Takahashi R, Markovic SN, Scrable HJ. Dominant effects of Δ40p53 on p53 function and melanoma cell fate. J Invest Dermatol 2014;134:791-800. [PMID: 24037342 DOI: 10.1038/jid.2013.391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
177 Huang W, Liu K. [P53 family proteins provide new insights into lung carcinogenesis and clinical treatment]. Zhongguo Fei Ai Za Zhi 2013;16:422-6. [PMID: 23945246 DOI: 10.3779/j.issn.1009-3419.2013.08.06] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta. PLoS One 2013;8:e61353. [PMID: 23630584 DOI: 10.1371/journal.pone.0061353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
179 Lee MK, Teoh WW, Phang BH, Tong WM, Wang ZQ, Sabapathy K. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell 2012;22:751-64. [PMID: 23238012 DOI: 10.1016/j.ccr.2012.10.022] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 8.0] [Reference Citation Analysis]
180 Janouskova H, Ray AM, Noulet F, Lelong-Rebel I, Choulier L, Schaffner F, Lehmann M, Martin S, Teisinger J, Dontenwill M. Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target α5 integrin in colon cancer cells. Cancer Lett. 2013;336:307-318. [PMID: 23523610 DOI: 10.1016/j.canlet.2013.03.018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
181 Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 2013;98:1130-6. [PMID: 23365123 DOI: 10.1210/jc.2012-2924] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 8.9] [Reference Citation Analysis]
182 Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemelä M, Khanna A, Chan EK, Kähäri VM, Kellokumpu-Lehtinen PL, Sansom OJ, Evan GI, Junttila MR, Ryan KM, Marine JC, Joensuu H, Westermarck J. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 2013;3:182-97. [PMID: 23306062 DOI: 10.1158/2159-8290.CD-12-0292] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 10.4] [Reference Citation Analysis]
183 Kandioler D, Kappel S, Wolf B. Designing p53 Trials: A Surgical Oncologists View. p53 in the Clinics 2013. [DOI: 10.1007/978-1-4614-3676-8_16] [Reference Citation Analysis]
184 Mori T. Understanding the pathological features of early oral cancer (Review Article). J Jpn Soc Oral Tumor 2013;25:42-53. [DOI: 10.5843/jsot.25.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
185 Tan EM. From rheumatic diseases to cancer - role of autoantibodies as diagnostic biomarkers. Arthritis Res Ther 2012;14:O2. [DOI: 10.1186/ar3557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
186 Bursać S, Brdovčak MC, Pfannkuchen M, Orsolić I, Golomb L, Zhu Y, Katz C, Daftuar L, Grabušić K, Vukelić I, Filić V, Oren M, Prives C, Volarevic S. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc Natl Acad Sci U S A 2012;109:20467-72. [PMID: 23169665 DOI: 10.1073/pnas.1218535109] [Cited by in Crossref: 135] [Cited by in F6Publishing: 141] [Article Influence: 13.5] [Reference Citation Analysis]
187 Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013;41:D962-D969. [PMID: 23161690 DOI: 10.1093/nar/gks1033] [Cited by in Crossref: 116] [Cited by in F6Publishing: 123] [Article Influence: 11.6] [Reference Citation Analysis]
188 Chiang YJ, Difilippantonio MJ, Tessarollo L, Morse HC, Hodes RJ. Exon 1 disruption alters tissue-specific expression of mouse p53 and results in selective development of B cell lymphomas. PLoS One 2012;7:e49305. [PMID: 23166633 DOI: 10.1371/journal.pone.0049305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
189 Bellini MF, Cadamuro AC, Succi M, Proença MA, Silva AE. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012;2012:891961. [PMID: 22919278 DOI: 10.1155/2012/891961] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 5.2] [Reference Citation Analysis]
190 Hasmats J, Green H, Solnestam BW, Zajac P, Huss M, Orear C, Validire P, Bjursell M, Lundeberg J. Validation of whole genome amplification for analysis of the p53 tumor suppressor gene in limited amounts of tumor samples. Biochemical and Biophysical Research Communications 2012;425:379-83. [DOI: 10.1016/j.bbrc.2012.07.101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
191 Takahashi R, Giannini C, Sarkaria JN, Schroeder M, Rogers J, Mastroeni D, Scrable H. p53 isoform profiling in glioblastoma and injured brain. Oncogene 2013;32:3165-74. [PMID: 22824800 DOI: 10.1038/onc.2012.322] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
192 Italiano A, Chen CL, Thomas R, Breen M, Bonnet F, Sevenet N, Longy M, Maki RG, Coindre JM, Antonescu CR. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer 2012;118:5878-87. [PMID: 22648906 DOI: 10.1002/cncr.27614] [Cited by in Crossref: 83] [Cited by in F6Publishing: 86] [Article Influence: 8.3] [Reference Citation Analysis]
193 Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, Sundström M, Micke P, Botling J, Soussi T. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A 2012;109:9551-6. [PMID: 22628563 DOI: 10.1073/pnas.1200019109] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 6.4] [Reference Citation Analysis]
194 Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, Vodicka P. Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer. Mutagenesis 2012;27:211-8. [PMID: 22294769 DOI: 10.1093/mutage/ger067] [Cited by in Crossref: 66] [Cited by in F6Publishing: 77] [Article Influence: 6.6] [Reference Citation Analysis]
195 Vinall RL, Chen JQ, Hubbard NE, Sulaimon SS, Shen MM, Devere White RW, Borowsky AD. Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression. Dis Model Mech 2012;5:914-20. [PMID: 22563073 DOI: 10.1242/dmm.008995] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
196 van der Weyden L, Rust AG, McIntyre RE, Robles-Espinoza CD, del Castillo Velasco-Herrera M, Strogantsev R, Ferguson-Smith AC, McCarthy S, Keane TM, Arends MJ. Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity. Oncogene. 2013;32:397-402. [PMID: 22370638 DOI: 10.1038/onc.2012.56] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
197 Stegh AH. Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets 2012;16:67-83. [PMID: 22239435 DOI: 10.1517/14728222.2011.643299] [Cited by in Crossref: 123] [Cited by in F6Publishing: 143] [Article Influence: 12.3] [Reference Citation Analysis]
198 Venook AP, Bendell JC, Warren RS. Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint. Am Soc Clin Oncol Educ Book 2012;:193-200. [PMID: 24451733 DOI: 10.14694/EdBook_AM.2012.32.50] [Reference Citation Analysis]
199 Lu H, Yang X, Duggal P, Allen CT, Yan B, Cohen J, Nottingham L, Romano RA, Sinha S, King KE, Weinberg WC, Chen Z, Van Waes C. TNF-α promotes c-REL/ΔNp63α interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. Cancer Res 2011;71:6867-77. [PMID: 21933882 DOI: 10.1158/0008-5472.CAN-11-2460] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
200 Gessi M, von Bueren AO, Rutkowski S, Pietsch T. p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease. J Neurooncol 2012;106:135-41. [PMID: 21796446 DOI: 10.1007/s11060-011-0648-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
201 Novak R, Zeng Y, Shuga J, Venugopalan G, Fletcher DA, Smith MT, Mathies RA. Single-cell multiplex gene detection and sequencing with microfluidically generated agarose emulsions. Angew Chem Int Ed Engl 2011;50:390-5. [PMID: 21132688 DOI: 10.1002/anie.201006089] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 10.5] [Reference Citation Analysis]
202 Peltonen JK, Vähäkangas KH, Helppi HM, Bloigu R, Pääkkö P, Turpeenniemi-Hujanen T. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study. Head Neck Oncol 2011;3:20. [PMID: 21513535 DOI: 10.1186/1758-3284-3-20] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
203 Sugawara W, Arai Y, Kasai F, Fujiwara Y, Haruta M, Hosaka R, Nishida K, Kurosumi M, Kobayashi Y, Akagi K, Kaneko Y. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome. Genes Chromosom Cancer 2011;50:535-45. [DOI: 10.1002/gcc.20878] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
204 Emami S. Interplay between p53-family, their regulators, and PARPs in DNA repair. Clin Res Hepatol Gastroenterol 2011;35:98-104. [PMID: 21177056 DOI: 10.1016/j.gcb.2010.10.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
205 Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol 2011;2011:583929. [PMID: 21331359 DOI: 10.1155/2011/583929] [Cited by in Crossref: 159] [Cited by in F6Publishing: 186] [Article Influence: 14.5] [Reference Citation Analysis]
206 Köbel M, Reuss A, Bois AD, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010;222:191-8. [DOI: 10.1002/path.2744] [Cited by in Crossref: 116] [Cited by in F6Publishing: 123] [Article Influence: 9.7] [Reference Citation Analysis]
207 Wang ZJ, Gong H, Gong D, Zhu SS. Transfection of the wild-type xeroderma pigmentosum group D gene alters the biological behavior of human cholangiocarcinoma cell line QBC939. Shijie Huaren Xiaohua Zazhi 2010; 18(15): 1531-1536 [DOI: 10.11569/wcjd.v18.i15.1531] [Reference Citation Analysis]
208 Lane D, Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2010;2:a000893. [PMID: 20463001 DOI: 10.1101/cshperspect.a000893] [Cited by in Crossref: 229] [Cited by in F6Publishing: 288] [Article Influence: 19.1] [Reference Citation Analysis]